Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS and Opdivo in R/R Hodgkin Lymphoma
December 11, 2017 10:31 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) and Bristol-Myers Squibb Company (NYSE: BMY) today highlighted updated interim results from an ongoing phase ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)